Breaking News


Mycophenolate mofetil versus cyclosporine A for treating chronic plaque-type psoriasis


A prospective, multicenter, randomized, open-label, parallel group trial compared the efficacy of cyclosporine A 2.5 mg/kg/day with mycophenolate mofetil 1 g b.i.d. for 12 weeks in 54 patients with chronic plaque-type psoriasis. The Psoriasis Area and Severity Index (PASI) was used to assess psoriatic severity and the primary outcome measure was the time to disease relapse. There was no difference in time to relapse between the two groups. However PASI scores fell significantly more in the cyclosporine A group than the mycophenolate mofetil group (P = 0.02), and the relative reduction in the PASI score was 79 and 49% I the cyclosporine A and mycophenolate mofetil groups, respectively (P = 0.004). ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list